Table 1

 Treatment characteristics and baseline disease activity

TreatmentActive/control groupNumber of patientsInterval (days)DAS28 baseline Mean (range)
*Mean (SEM).
MethotrexateActive151126.15 (4.50–7.83)
LeflunomideActive151126.05 (4.38–7.31)
PrednisoneActive10146.26 (4.58–7.98)
InfliximabActive20276.07 (4.14–8.21)
CCR1 antagonistActive10145.84 (4.31–6.95)
Stable MTXControl625.97 (4.22–8.21)
Stable DMARDControl12145.69 (3.43–7.59)
Overall8853 (5)*6.02 (0.11)*